題名:NAT2 fast acetylator genotypes are associated with an
increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan
作者:白冠壬; 余明治; 李俊年
Lee CN; Yu MC; Bai KJ; Chang JH; Fang CL; Hsu HL; Huang BS; Lu PC; Liu HE
貢獻者:呼吸治療學系
上傳時間:2009-08-24T03:32:16Z
摘要:Identifying the risk factors responsible for lung cancer especially for nonsmokers is critical for both its
prevention and treatment. Studies have linked the polymorphisms in N-acetyltransferases (NAT2), a key enzyme for metabolism of hydrocarbons, with lung cancer in Asian female nonsmokers. Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2
polymorphisms might represent a risk factor in lung
cancer with EGFR mutations. We studied NAT polymorphisms in 117 nonsmall cell lung cancer (NSCLC) patients and in 119 healthy controls and EGFR hotspot mutations in exons 18-21 in 100 of the 117 patients using polymerase chain reactions. NAT2 fast acetylator genotypes were
significantly associated with patients with lung cancer (P = 0.04, odds ratio (OR): 1.90, 95% confidence
interval (CI): 1.02-3.57). Further analyses revealed that NAT2 fast acetylator genotypes were significantly associated with NSCLC with wildtype EGFR (P = 0.008, OR: 3.16, 95% CI: 1.31-7.63), but not with those with EGFR mutations (P = 0.40). Therefore, NAT2 fast acetylator genotypes are a potential risk factor especially for lung cancer with wildtype EGFR
Identifying the risk factors responsible for lung cancer especially for nonsmokers is critical for both its
prevention and treatment. Studies have linked the polymorphisms in N-acetyltransferases (NAT2), a key
enzyme for metabolism of hydrocarbons, with lung cancer in Asian female nonsmokers. Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2
polymorphisms might represent a risk factor in lung
cancer with EGFR mutations. We studied NAT polymorphisms in 117 nonsmall cell lung cancer (NSCLC) patients and in 119 healthy controls and EGFR hotspot mutations in exons 18-21 in 100 of the 117 patients using polymerase chain reactions. NAT2 fast acetylator genotypes were
significantly associated with patients with lung cancer (P = 0.04, odds ratio (OR): 1.90, 95% confidence
interval (CI): 1.02-3.57). Further analyses revealed that NAT2 fast acetylator genotypes were significantly associated with NSCLC with wildtype EGFR (P = 0.008, OR: 3.16, 95% CI: 1.31-7.63), but not with those with EGFR mutations (P = 0.40). Therefore, NAT2 fast acetylator genotypes are a potential risk factor especially for lung cancer with wildtype EGFR.
